

ALKERMES INC  
Form 8-K  
May 27, 2005

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): May 27, 2005

**ALKERMES, INC.**

(Exact Name of Registrant as Specified in its Charter)

**PENNSYLVANIA**  
(State or Other Jurisdiction of  
Incorporation)

**1-14131**  
(Commission  
File Number)

**23-2472830**  
(I.R.S. Employer  
Identification No.)

**88 Sidney Street**  
**Cambridge, Massachusetts**  
(Address of principal executive offices)

**02139**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 8.01 Other Events

SIGNATURE

EX-99.1 Alkermes, Inc.

---

**Table of Contents**

**Item 8.01 Other Events**

On May 27, 2005, Alkermes, Inc. announced that the New Drug Application ( NDA ) for Vivitrol® (naltrexone long-acting injection) has been accepted for review by the United States Food and Drug Administration ( FDA ) and has been granted a Priority Review designation. A copy of the press release is attached hereto as Exhibit 99.1.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: May 27, 2005

By: /s/ James M. Frates

James M. Frates  
Vice President, Chief Financial Officer and  
Treasurer

---

**Table of Contents**

**EXHIBIT INDEX**

- 99.1 Press Release issued by the Company on May 27, 2005 announcing priority review granted for Vivitrex® (naltrexone long-acting injection) NDA submission